Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
123 hedge funds and large institutions have $490M invested in Five Prime Therapeutics, Inc. in 2018 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 24 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 34
28% more call options, than puts
Call options by funds: $1.67M | Put options by funds: $1.3M
4% less funds holding
Funds holding: 128 → 123 (-5)
12% less capital invested
Capital invested by funds: $555M → $490M (-$64.8M)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$19.7M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.84M |
| 3 |
BlackRock
New York
|
+$3.67M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.58M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.3M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$7.17M |
| 3 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$4.54M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.83M |
| 5 |
Axa
Paris,
France
|
-$3.79M |
FPRX Hedge Fund Activity: Q2 2018 in Review
123 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2018, worth a combined $490M — down 12% from $555M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of FPRX and 19 opened new positions — a net loss of 5 holders — while 34 trimmed existing stakes and 50 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $19.7M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.3M sold.
- 123 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2018, down from 128 in Q1 2018.
- Funds reported $490M of Five Prime Therapeutics, Inc. stock for Q2 2018, down 12% quarter-over-quarter.
- 19 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2018 and 24 closed out, a net change of -5 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q2 2018 was BVF Inc, an estimated $19.7M added.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2018 was EcoR1 Capital, an estimated $21.3M sold.
Based on aggregated 13F filings for Q2 2018.